Back to top
more

Bioventus (BVS)

(Delayed Data from NSDQ)

$6.14 USD

6.14
936,434

-0.18 (-2.85%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $6.14 0.00 (0.00%) 6:16 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (91 out of 246)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Why Grifols (GRFS) Stock Price Moved Up 7% on Wednesday

by Zacks Equity Research

A Bloomberg article suggests that Brookfield Asset Management is in discussions with banks to raise nearly $11 billion to fund the takeover of Spain-based Grifols (GRFS).

Zacks Equity Research

Amicus (FOLD) Banks on Galafold, High Dependence a Concern

by Zacks Equity Research

Amicus' (FOLD) lead drug, Galafold, is witnessing solid sales uptake so far. The approval for Pombiliti + Opfolda also aids sales. However, overdependence on Galafold for revenues remains a concern.

Zacks Equity Research

J&J (JNJ) to Boost MedTech Business With V-Wave Acquisition

by Zacks Equity Research

Johnson & Johnson (JNJ) inks a definitive agreement to acquire V-Wave Ltd. for an upfront payment of $600 million. The deal is likely to strengthen the company's MedTech business unit further.

Zacks Equity Research

GSK's ADC Drug for Lung Cancer Gets FDA's Breakthrough Tag

by Zacks Equity Research

The FDA bestows a Breakthrough Therapy Designation to GSK's B7-H3-targeted antibody-drug conjugate, GSK5764227, for relapsed/refractory extensive-stage small-cell lung cancer.

Zacks Equity Research

Zacks Industry Outlook Highlights Corcept, Amneal, Bioventus, Foghorn and Akebia

by Zacks Equity Research

Corcept, Amneal, Bioventus, Foghorn and Akebia have been highlighted in this Industry Outlook article.

Kinjel Shah headshot

5 Small Drug Stocks to Buy as Innovation Reaches Peak

by Kinjel Shah

Innovation is at its peak for the Zacks Medical-Drugs industry. CORT, AMRX, BVS, FHTX, and AKBA may prove to be good additions to one's portfolio.

Zacks Equity Research

Merck (MRK) Gets Exclusive Rights to Opevesostat From Partner

by Zacks Equity Research

Merck (MRK) exercises the option that will convert the collaboration deal with partner Orion for prostate cancer candidate opevesostat into a license agreement.

Zacks Equity Research

Encompass Health (EHC) Expands in Louisville With New Rehab Unit

by Zacks Equity Research

Encompass Health (EHC) and Baptist Health inaugurate a 40-bed inpatient rehabilitation hospital in Louisville, enhancing regional care and expanding EHC's network to 163 facilities.

Zacks Equity Research

Here's Why Investors Must Hold on to Centene (CNC) Stock Now

by Zacks Equity Research

Centene (CNC) is expected to benefit from expanding margins in the Marketplace business, contract wins in Medicaid, and improved Medicare Advantage Star ratings.

Zacks Equity Research

Compelling Reasons to Hold on to Cigna (CI) Stock for Now

by Zacks Equity Research

Cigna (CI) remains well-poised for growth on the back of improved pharmacy revenues in its Evernorth unit. Solid cash-generating abilities also enable it to tactically deploy capital.

Zacks Equity Research

Here's Why You Should Consider Buying Bioventus (BVS) Stock

by Zacks Equity Research

Here, we discuss some reasons why buying Bioventus (BVS) stock now may turn out to be a prudent move.

Zacks Equity Research

J&J (JNJ) Seeks Expanded Use of HIV Drug in US and Europe

by Zacks Equity Research

J&J (JNJ) seeks expanded use of its HIV-1 therapy, Prezcobix, for younger kids in the United States and Europe.

Zacks Equity Research

Humana (HUM) Partners With UAB to Boost Care for MA Members

by Zacks Equity Research

Humana (HUM) expands its Medicare Advantage network in Alabama through a new partnership with UAB Health System, offering greater access to enhanced healthcare services.

Zacks Equity Research

Biogen (BIIB) Gets EU Approval for Rare Disease Drug Qalsody

by Zacks Equity Research

Biogen's (BIIB) Qalsody is the first therapy approved to treat a rare genetic form of ALS in Europe

Zacks Equity Research

Merck (MRK) to Buy Private Ophthalmology Company EyeBio

by Zacks Equity Research

Merck's (MRK) acquisition of EyeBio is set to add the latter's lead pipeline candidate, Restoret, a novel Wnt agonist antibody being developed for treating retinal diseases.

Zacks Equity Research

J&J (JNJ) to Buy Rights to Novel Atopic Dermatitis Candidate

by Zacks Equity Research

J&J (JNJ) is set to acquire Yellow Jersey Therapeutics, which holds NM26 rights, from Numab's shareholder, for a purchase price of $1.25 billion in cash.

Zacks Equity Research

Here's Why You Should Buy Acrivon Therapeutics (ACRV) Stock

by Zacks Equity Research

Here, we discuss some reasons why buying Acrivon Therapeutics (ACRV) stock now may turn out to be a prudent move.

Kinjel Shah headshot

5 Small Drug Stocks to Buy From a Recovering Industry

by Kinjel Shah

Innovation is expected to continue to drive the growth of the Zacks Medical-Drugs industry. HRTX, BVS, AQST, ACRV and CRDL may prove to be good additions to one's portfolio.

Zacks Equity Research

Here's Why You Should Retain Centene (CNC) Stock for Now

by Zacks Equity Research

Centene (CNC) remains well-poised for growth on the back of sound growth in membership, divestitures and a growing cash balance.

Zacks Equity Research

PTC Therapeutics (PTCT) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

PTC Therapeutics (PTCT) delivered earnings and revenue surprises of -182.76% and 2.80%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Bioventus (BVS) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

On Bioventus' (BVS) third-quarter 2023 earnings call, investors' focus is likely to be on the sales numbers of its three business units - pain treatments, restorative therapies and surgical solutions.

Indrajit Bandyopadhyay headshot

3 Value Medical Stocks to Buy for Safety Amid Market Volatility

by Indrajit Bandyopadhyay

We have narrowed our search to three value stocks from the Medical sector. These are PHG, RDNT and BVS.

Zacks Equity Research

Zevra Therapeutics (ZVRA) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Zevra Therapeutics (ZVRA) delivered earnings and revenue surprises of -30.77% and 3.94%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

AcelRx Pharmaceuticals (ACRX) Reports Break-Even Earnings for Q1

by Zacks Equity Research

AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of 100% and 100%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Durect (DRRX) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Durect (DRRX) delivered earnings and revenue surprises of -4% and 41.81%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?